Page last updated: 2024-11-11

n-valproyl glycinamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

TV 1901: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6918293
CHEMBL ID471638
SCHEMBL ID4014030
MeSH IDM0282766

Synonyms (41)

Synonym
spd-493
tv-1901
tvp-1901
valrocemide
valproyl glycinamide
D02718
92262-58-3
valrocemide (usan/inn)
tv 1901
SCHEMBL4014030
CHEMBL471638
n-(2-amino-2-oxoethyl)-2-propylpentanamide
n-valproyl glycinamide
pentanamide, n-(2-amino-2-oxoethyl)-2-propyl-
n-valproylglycinamide
vpgd cpd
unii-1c7go6ow7l
n-(carbamoylmethyl)-2-propylvaleramide
valrocemide [usan:inn]
1c7go6ow7l ,
n-(carbamoylmethyl)-2-propylpentanamide
AKOS017548022
pentanamide, n-(2-amino-2-oxoethyl)-2-propyl
valrocemide [inn]
valrocemide [usan]
mfcd00870963
SY028535
DTXSID70238939
A903090
valrocemide (tv1901,vgd))
HY-100379
CS-7525
BCP25525
DB06657
tv1901
valrocemide,tv 1901
Q27252221
MS-23084
n-valproylglycinamide; n-(2-amino-2-oxoethyl)-2-propylpentanamide;n-(2-amino-2-oxoethyl)-2-propylpentanamide
EN300-125611
Z1269244696

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Of the N-alkyl VGD derivatives studied, M-VGD had the best pharmacokinetic profile: the lowest clearance (5."( Structure-pharmacokinetic-pharmacodynamic relationships of N-alkyl derivatives of the new antiepileptic drug valproyl glycinamide.
Bialer, M; Spiegelstein, O; Yagen, B, 1999
)
0.3
"M-VGD had the most favorable pharmacodynamic and pharmacokinetic profile of the investigated N-alkyl VGD derivatives."( Structure-pharmacokinetic-pharmacodynamic relationships of N-alkyl derivatives of the new antiepileptic drug valproyl glycinamide.
Bialer, M; Spiegelstein, O; Yagen, B, 1999
)
0.3
" We utilized pharmacokinetic considerations in designing various amide derivatives of VPA which are more potent as anticonvulsants than VPA and have the potential to be nonteratogenic and nonhepatotoxic."( Pharmacokinetic considerations in the design of better and safer new antiepileptic drugs.
Bialer, M, 1999
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID395095Ratio of valproic acid ED50 to compound ED50 in albino mouse after 0.5 hrs by MES test2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Synthesis and anticonvulsant activity of amino acid-derived sulfamides.
AID395091Anticonvulsant activity in ip dosed albino mouse after 0.5 hrs by MES test2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Synthesis and anticonvulsant activity of amino acid-derived sulfamides.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (57.14)18.2507
2000's3 (42.86)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.00

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.00 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.31 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.00)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (22.22%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (77.78%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]